ContractRevenue Interest Assignment Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionEX-10.3 4 pdli-201593010qex103.htm REVENUE INTEREST ASSIGNMENT AGREEMENT Exhibit 10.3 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* * *” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. REVENUE INTEREST ASSIGNMENT AGREEMENT Dated as of July 28, 2015 between ARIAD PHARMACEUTICALS, INC. and PDL BIOPHARMA, INC. Table of Contents
REVENUE INTEREST ASSIGNMENT AGREEMENTRevenue Interest Assignment Agreement • November 4th, 2015 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 4th, 2015 Company Industry JurisdictionThis REVENUE INTEREST ASSIGNMENT AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of July 28, 2015, by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation (“ARIAD” or the “Company”), and PDL BioPharma, Inc., a Delaware corporation (“Purchaser”).